Literature DB >> 15527677

New insights into the pathogenesis of inflammatory bowel disease.

Gil Y Melmed1, Maria T Abreu.   

Abstract

Several important advances have been made over the past few years that have expanded our knowledge of the immunology of the gut and its complex interactions with commensal organisms. Critical developments in our understanding of the pathogenesis of inflammatory bowel diseases include the discovery of Toll-like receptors and the identification of not one but two susceptibility genes for Crohn's disease. We have furthered our understanding significantly concerning the role of dendritic cells in the development of gut inflammation. In addition, a novel hypothesis suggesting a protective role for helminthic infections is gaining experimental evidence and direct clinical applicability. In this review we summarize these key developments in the pathophysiology of inflammatory bowel disease and attempt to ascribe clinical relevance where applicable.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15527677     DOI: 10.1007/s11894-004-0069-3

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  58 in total

Review 1.  Epidemiology of inflammatory bowel disease in Asia.

Authors:  S K Yang; E V Loftus; W J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2001-08       Impact factor: 5.325

2.  Metabolic induction of experimental ulcerative colitis by inhibition of fatty acid oxidation.

Authors:  W E Roediger; S Nance
Journal:  Br J Exp Pathol       Date:  1986-12

3.  Probiotic bacteria enhance murine and human intestinal epithelial barrier function.

Authors:  K Madsen; A Cornish; P Soper; C McKaigney; H Jijon; C Yachimec; J Doyle; L Jewell; C De Simone
Journal:  Gastroenterology       Date:  2001-09       Impact factor: 22.682

4.  Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model.

Authors:  Catherine Van Montfrans; Maria Sol Rodriguez Pena; Inge Pronk; Fiebo J W Ten Kate; Anje A Te Velde; Sander J H Van Deventer
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

5.  Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.

Authors:  Paolo Gionchetti; Fernando Rizzello; Ulf Helwig; Alessandro Venturi; Karen Manon Lammers; Patrizia Brigidi; Beatrice Vitali; Gilberto Poggioli; Mario Miglioli; Massimo Campieri
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

6.  Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis.

Authors:  Helga-Paula Török; Jürgen Glas; Laurian Tonenchi; Thomas Mussack; Christian Folwaczny
Journal:  Clin Immunol       Date:  2004-07       Impact factor: 3.969

7.  NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses.

Authors:  Tomohiro Watanabe; Atsushi Kitani; Peter J Murray; Warren Strober
Journal:  Nat Immunol       Date:  2004-06-27       Impact factor: 25.606

8.  Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease.

Authors:  Naohiro Inohara; Yasunori Ogura; Ana Fontalba; Olga Gutierrez; Fernando Pons; Javier Crespo; Koichi Fukase; Seiichi Inamura; Shoichi Kusumoto; Masahito Hashimoto; Simon J Foster; Anthony P Moran; Jose L Fernandez-Luna; Gabriel Nuñez
Journal:  J Biol Chem       Date:  2003-01-04       Impact factor: 5.157

9.  Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease.

Authors:  William S Mow; Simon K Lo; Stephan R Targan; Marla C Dubinsky; Leo Treyzon; Maria T Abreu-Martin; Konstantinos A Papadakis; Eric A Vasiliauskas
Journal:  Clin Gastroenterol Hepatol       Date:  2004-01       Impact factor: 11.382

Review 10.  Probiotics and the management of inflammatory bowel disease.

Authors:  Richard N Fedorak; Karen L Madsen
Journal:  Inflamm Bowel Dis       Date:  2004-05       Impact factor: 5.325

View more
  2 in total

Review 1.  Future biologic targets for IBD: potentials and pitfalls.

Authors:  Gil Y Melmed; Stephan R Targan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02       Impact factor: 46.802

2.  Elevation of PRKCDBP, a novel transcriptional target of TNF-α, and its downregulation by infliximab in patients with ulcerative colitis.

Authors:  Jung-Wook Kim; Hyo Jong Kim; Chang Kyun Lee; Jae-Jun Shim; Jae Young Jang; Suk Ho Dong; Byung-Ho Kim; Young Woon Chang; Sung-Gil Chi
Journal:  Dig Dis Sci       Date:  2014-07-23       Impact factor: 3.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.